Gilead Sciences | Capitaux Propres Et Réserves



Equity Capital And Reserves Changement Date
AbbVie USD 1.46B 1.86B 2025-03
Agios Pharmaceuticals USD 1.37B 96.97M 2025-06
ALKERMES USD 1.62B 113M 2025-06
Alnylam Pharmaceuticals USD 250.59M 135.16M 2025-06
Amgen USD 7.43B 1.22B 2025-06
Biogen USD 17.63B 655.3M 2025-06
BioMarin Pharmaceutical USD 6.03B 233.65M 2025-06
Bristol-Myers Squibb USD 17.49B 100M 2025-06
Eli Lilly USD 18.27B 2.43B 2025-06
Gilead Sciences USD 19.67B 596M 2025-06
GlaxoSmithKline GBP 14.35B 197M 2025-06
Glaxosmithkline GBP 13.67B 337M 2024-12
Incyte USD 4.17B 503.34M 2025-06
J&J USD 78.11B 6.62B 2025-03
Merck USD 49.06B 725M 2025-06
Moderna USD 9.4B 667M 2025-06
Neurocrine Biosciences USD 2.69B 158.6M 2025-06
Novartis USD 42.05B 3.6B 2025-06
Pfizer USD 88.7B 1.64B 2025-06
PTC Therapeutics USD -206546000 20.79M 2025-06
Regeneron Pharmaceuticals USD 29.94B 551.3M 2025-06
Sanofi 70.28B 3.8B 2025-06
Sarepta Therapeutics USD 1.36B 214.66M 2025-06
United Therapeutics USD 7.17B 366.4M 2025-06
Vertex Pharmaceuticals USD 17.18B 679.1M 2025-06


Gilead Sciences Capitaux Propres Et Réserves - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.